Marker Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

MRKR$0.99+10.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


	For the Years Ended
· · December 31,
	2024		2023
Revenues:
Grant income		$6,591,080		$3,311,133
Total revenues		6,591,080		3,311,133
Operating expenses:
Research and development		13,467,845		10,416,789
General and administrative		4,241,607		7,475,722
Total operating expenses		17,709,452		17,892,511
Loss from operations		(11,118,372)		(14,581,378)
Other income (expenses):
Interest income		437,010		539,158
Loss from continuing operations before income taxes		(10,681,362)		(14,042,220)
Income tax expense		49,953		3,675
Net loss from continuing operations		(10,731,315)		(14,045,895)

Discontinued operations:
Loss from discontinued operations		—		(2,922,406)
Gain on disposal of discontinued operations, net of $63,000 in tax		—		8,731,487
Income (loss) from discontinued operations		—		5,809,081
Net loss		$(10,731,315)		$(8,236,814)

Net earnings (loss) per share:
Loss from continuing operations, basic and diluted		$(1.19)		$(1.59)
Income from discontinued operations, basic and diluted		$—		$0.66
Net loss per share, basic and diluted		$(1.19)		$(0.94)

Weighted average number of common shares outstanding:
Basic		8,980,207		8,809,382
Diluted		8,980,207		8,809,382

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.